In VivoRare disease has become a real area of focus and growth for drug development. According to Citeline’s Pharma R&D Annual Review 2023 , more than 30% of all drug development is targeted against rar
ScripAstraZeneca PLC has an ambitious goal to move from the number four cancer drug company in the world toward the top ranking and is relying on a diverse pipeline to continue the company’s impressive gr
ScripAstraZeneca has been on a sector-beating growth streak since 2018, but this could tail off in the coming years as its biggest earning therapies mature. The company believes it can sustain this perfor
ScripChina has become more cutting edge in terms of innovation rather than being a fast follower and AstraZeneca PLC , the long-time commercial leader there among foreign pharma firms, is determined to pa